Seilern Investment Management Ltd Has $51.36 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Seilern Investment Management Ltd lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 20.7% during the second quarter, Holdings Channel.com reports. The firm owned 97,560 shares of the company’s stock after acquiring an additional 16,729 shares during the quarter. IDEXX Laboratories makes up 6.5% of Seilern Investment Management Ltd’s investment portfolio, making the stock its 5th biggest holding. Seilern Investment Management Ltd’s holdings in IDEXX Laboratories were worth $51,359,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. SHP Wealth Management acquired a new stake in IDEXX Laboratories in the fourth quarter valued at $26,000. Elevation Wealth Partners LLC lifted its holdings in IDEXX Laboratories by 188.2% during the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after buying an additional 32 shares during the period. Virtus Advisers LLC bought a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at about $26,000. WealthCollab LLC bought a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at about $30,000. Finally, Arlington Trust Co LLC increased its stake in shares of IDEXX Laboratories by 46.3% in the second quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock valued at $32,000 after buying an additional 19 shares during the period. Institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on IDXX shares. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, July 29th. Citigroup upped their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Finally, UBS Group raised their price target on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $756.00.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $586.67 on Friday. The company has a fifty day moving average of $559.73 and a 200-day moving average of $585.79. The firm has a market capitalization of $46.22 billion, a P/E ratio of 41.26, a P/E/G ratio of 3.18 and a beta of 1.54. The company has a quick ratio of 0.82, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a twelve month low of $518.55 and a twelve month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.94 by $0.33. The business had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. IDEXX Laboratories’s revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the firm earned $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 14.82 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.